Latest & greatest articles for oxycodone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on oxycodone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on oxycodone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for oxycodone

1. Oxycodone

Oxycodone Top results for oxycodone - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search (...) button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for oxycodone The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory

Trip Latest and Greatest2018

2. Can early oral prolonged-release oxycodone with or without naloxone reduce the duration of epidural analgesia after cystectomy? A 3-arm, randomized, double-blind, placebo-controlled trial

Can early oral prolonged-release oxycodone with or without naloxone reduce the duration of epidural analgesia after cystectomy? A 3-arm, randomized, double-blind, placebo-controlled trial 29189517 2017 12 12 1872-6623 2017 Nov 20 Pain Pain Can early oral prolonged-release oxycodone with or without naloxone reduce the duration of epidural analgesia after cystectomy? A 3-arm, randomized, double-blind, placebo-controlled trial. 10.1097/j.pain.0000000000001112 Thoracic epidural analgesia (TEA (...) ) enhances recovery after bowel surgery. Early postoperative prolonged-release oral formulation of oxycodone or oxycodone/naloxone is potentially useful as a second analgesic step to reduce the duration of TEA. We hypothesized that oxycodone would decrease the duration of TEA and combined with naloxone preserve gastrointestinal function. Ninety patients undergoing open cystectomy and urinary diversion were enrolled in this randomized double-blind, three-arm, parallel-group, placebo-controlled single

EvidenceUpdates2018

3. Effect of oxycodone patient-controlled intravenous analgesia after cesarean section: a randomized controlled study

Effect of oxycodone patient-controlled intravenous analgesia after cesarean section: a randomized controlled study 29180891 2017 12 19 1178-7090 10 2017 Journal of pain research J Pain Res Effect of oxycodone patient-controlled intravenous analgesia after cesarean section: a randomized controlled study. 2649-2655 10.2147/JPR.S142896 Oxycodone is a semisynthetic μ-opioid receptor agonist with a potentially good analgesic efficacy in visceral pain. This study aims to compare the efficacy (...) of oxycodone with sufentanil patient-controlled intravenous analgesia (PCIA). One hundred and twenty primiparas undergoing elective cesarean section were randomized into four groups by different drugs of PCIA: group S (sufentanil 100 μg), group OS1 (sufentanil 70 μg, oxycodone 30 mg), group OS2 (sufentanil 50 μg, oxycodone 50 mg), and group O (oxycodone 100 mg). Ramosetron 0.3 mg was added to each group. In all groups, drugs were diluted to 100 mL and managed with a continuous infusion of 1 mL·h-1, a bolus

EvidenceUpdates2018 Full Text: Link to full Text with Trip Pro

4. A randomized, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-releas

A randomized, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-releas 28860850 2017 09 01 2017 09 03 1178-7090 10 2017 Journal of pain research J Pain Res A randomized, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer (...) -naïve patients with cancer pain not relieved by non-opioid analgesics. This was a multicenter, randomized, double-blind, parallel-group trial. A double-dummy method was used for blinding. Each randomized subject received either hydromorphone extended-release tablets plus placebo oxycodone hydrochloride extended-release tablets 4 mg/day (n=88) or placebo hydromorphone extended-release tablets plus oxycodone hydrochloride extended-release tablets 10 mg/day (n=93) orally for 7 days (once-daily dosing

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

5. Oxycodone for pain in fibromyalgia in adults.

Oxycodone for pain in fibromyalgia in adults. BACKGROUND: This review replaces part of an earlier review that evaluated oxycodone for both neuropathic pain and fibromyalgia, which has now been split into separate reviews for the two conditions. This review will consider pain in fibromyalgia only.Opioid drugs are commonly used to treat fibromyalgia, but they may not be beneficial for people with this condition. Most reviews have examined all opioids together. This review sought evidence (...) specifically for oxycodone, at any dose, and by any route of administration. OBJECTIVES: To assess the analgesic efficacy and adverse events of oxycodone for treating pain in fibromyalgia in adults. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and EMBASE for randomised controlled trials from inception to 25 July 2016. We also searched the reference lists of retrieved studies and reviews, and searched online clinical trial registries. SELECTION CRITERIA

Cochrane2016

6. Comparative Analgesic Efficacy of Oxycodone/Acetaminophen Versus Hydrocodone/Acetaminophen for Short-term Pain Management in Adults Following ED Discharge

Comparative Analgesic Efficacy of Oxycodone/Acetaminophen Versus Hydrocodone/Acetaminophen for Short-term Pain Management in Adults Following ED Discharge 26479162 2015 11 09 2016 06 02 2015 11 09 1553-2712 22 11 2015 Nov Academic emergency medicine : official journal of the Society for Academic Emergency Medicine Acad Emerg Med Comparative Analgesic Efficacy of Oxycodone/Acetaminophen Versus Hydrocodone/Acetaminophen for Short-term Pain Management in Adults Following ED Discharge. 1254-60 (...) 10.1111/acem.12813 The objective was to test the hypothesis that oxycodone/acetaminophen provides superior analgesia to hydrocodone/acetaminophen for the treatment of acute extremity pain following emergency department (ED) discharge. This was a prospective, randomized, double-blind clinical trial of nonelderly adult ED patients with acute musculoskeletal extremity pain, randomly allocated at discharge to receive oxycodone/acetaminophen (5 mg/325 mg) or hydrocodone/acetaminophen (5 mg/325 mg

EvidenceUpdates2015

7. Naproxen With Cyclobenzaprine, Oxycodone/Acetaminophen, or Placebo for Treating Acute Low Back Pain: A Randomized Clinical Trial.

Naproxen With Cyclobenzaprine, Oxycodone/Acetaminophen, or Placebo for Treating Acute Low Back Pain: A Randomized Clinical Trial. 26501533 2015 10 27 2015 11 04 2016 10 17 1538-3598 314 15 2015 Oct 20 JAMA JAMA Naproxen With Cyclobenzaprine, Oxycodone/Acetaminophen, or Placebo for Treating Acute Low Back Pain: A Randomized Clinical Trial. 1572-80 10.1001/jama.2015.13043 Low back pain (LBP) is responsible for more than 2.5 million visits to US emergency departments (EDs) annually. These patients (...) are usually treated with nonsteroidal anti-inflammatory drugs, acetaminophen, opioids, or skeletal muscle relaxants, often in combination. To compare functional outcomes and pain at 1 week and 3 months after an ED visit for acute LBP among patients randomized to a 10-day course of (1) naproxen + placebo; (2) naproxen + cyclobenzaprine; or (3) naproxen + oxycodone/acetaminophen. This randomized, double-blind, 3-group study was conducted at one urban ED in the Bronx, New York City. Patients who presented

JAMA2015

10. Oxycodone

Oxycodone Scottish Palliative Care Guidelines - Oxycodone Scottish Palliative Care Guidelines search / / / Oxycodone Oxycodone Introduction Description : Potent, synthetic opioid analgesic; used second line. Preparations Table 1 Oxycodone In Palliative Care Oxycodone Preparations Oral Immediate release oxycodone OxyNorm® capsules Shortec® and Lynlor® also available. OxyNorm ® liquid Generic 5mg, 10mg, 20mg 1mg/ml, 10mg/ml Modified release (long acting) oxycodone OxyContin ®, Longtec®, Oxylan (...) ® NB: depending on brand not all strengths available 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 60mg, 80mg, 120mg (check local guidance for preferred brand -not all strengths may be stocked) Injection Oxycodone injection OxyNorm ® injection 10mg/ml, 20mg/2ml, 50mg/ml (non- formulary in some health boards) Oxycodone in Palliative Care: Preparations - Version 1 June 2014 Indications Second line oral and injectable analgesic for moderate to severe opioid responsive pain in patients unable to tolerate oral

Scottish Palliative Care Guidelines2015

11. Oxycodone

Oxycodone USE OF OXYCODONE IN PREGNANCY 0344 892 0909 USE OF OXYCODONE IN PREGNANCY (Date of issue: May 2016 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Oxycodone is a semisynthetic opioid analgesic administered orally (...) , intramuscularly or intravenously for the treatment of moderate to severe pain. The available data concerning the fetal effects of maternal oxycodone use in pregnancy are limited, consisting of approximately 500 pregnancies described in four uncontrolled case reports and five controlled studies. One case report and one controlled study relate to recreational oxycodone exposure specifically. The results of these studies do not currently indicate that maternal therapeutic use of oxycodone in early pregnancy

UK Teratology Information Service2014

12. Targiniq ER (oxycodone hydrochloride/naloxone hydrochloride)

Targiniq ER (oxycodone hydrochloride/naloxone hydrochloride) Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - TARGINIQ ER (oxycodone hydrochloride/naloxone hydrochloride) Extended-Release Tablets Company: Purdue Pharma, L.P. Application No.: 205777 Approval Date: 7/23/2014 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF

FDA - Drug Approval Package2014

13. Cohort study: Oxycodone administered as postpartum pain relief is associated with maternal report of infant central nervous system depression in breastfed infants

Cohort study: Oxycodone administered as postpartum pain relief is associated with maternal report of infant central nervous system depression in breastfed infants Oxycodone administered as postpartum pain relief is associated with maternal report of infant central nervous system depression in breastfed infants | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Oxycodone administered as postpartum pain relief is associated with maternal report of infant central nervous system depression in breastfed infants Article Text Harm Cohort study Oxycodone

Evidence-Based Medicine (Requires free registration)2013

15. Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine

Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release (...) evaluated the cost-effectiveness of tapentadol prolonged release, compared with oxycodone controlled release, for severe non-malignant chronic pain in patients for whom controlled-release morphine was ineffective or not tolerated. The authors concluded that tapentadol was less costly and more effective than oxycodone. The study was generally well reported and used appropriate methods. There were some issues stemming from a lack of available evidence, but the authors' conclusion seems plausible

NHS Economic Evaluation Database.2012

16. Efficacy and tolerability of oxycodone in moderate-severe cancer-related pain: a meta-analysis of randomized controlled trials

Efficacy and tolerability of oxycodone in moderate-severe cancer-related pain: a meta-analysis of randomized controlled trials Efficacy and tolerability of oxycodone in moderate-severe cancer-related pain: a meta-analysis of randomized controlled trials Efficacy and tolerability of oxycodone in moderate-severe cancer-related pain: a meta-analysis of randomized controlled trials Wang YM, Liu ZW, Liu JL, Zhang L CRD summary The authors concluded that oxycodone was superior to other strong opioids (...) including morphine sulphate, codeine and tramadol, supporting its use as an opioid for cancer-related pain in China. This was a well-conducted review and the results are likely reliable. Authors' objectives To evaluate the efficacy and tolerability of oxycodone in moderate-severe cancer-related pain in China. Searching PubMed, EMBASE, The Cochrane Library and CBM databases were searched to August 2011 without language restrictions; search terms were reported. A manual search of references from major

DARE.2012

17. Oral oxycodone offers equivalent analgesia to intravenous patient-controlled analgesia after total hip replacement: a randomized, single-centre, non-blinded, non-inferiority study

Oral oxycodone offers equivalent analgesia to intravenous patient-controlled analgesia after total hip replacement: a randomized, single-centre, non-blinded, non-inferiority study Oral oxycodone offers equivalent analgesia to intravenous patient-controlled analgesia after total hip replacement: a randomized, single-centre, non-blinded, non-inferiority study Oral oxycodone offers equivalent analgesia to intravenous patient-controlled analgesia after total hip replacement: a randomized, single (...) -centre, non-blinded, non-inferiority study Rothwell MP, Pearson D, Hunter JD, Mitchell PA, Graham-Woollard T, Goodwin L, Dunn G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to establish whether oral oxycodone could

NHS Economic Evaluation Database.2011

18. The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain

The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain 21304148 2011 02 25 2011 04 21 2013 11 21 1526-7598 112 3 2011 Mar Anesthesia and analgesia Anesth. Analg. The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain. 693-702 10.1213/ANE (...) .0b013e318209d320 Current clinical guidelines have identified the need for studies comparing the effect of different short-acting or rapid-onset opioids for the treatment of breakthrough pain (BTP). In this study we evaluated the efficacy and safety of treatment with fentanyl buccal tablet (FBT) in comparison with immediate-release oxycodone in alleviating BTP in opioid-tolerant patients with chronic pain. In this cross-over design study, opioid-tolerant patients were randomized to open-label titration with FBT

EvidenceUpdates2011

20. A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin

A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin 19962354 2010 05 04 2010 08 17 2015 11 19 1528-8447 11 5 2010 May The journal of pain : official journal of the American Pain Society J Pain A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. 462-71 10.1016/j.jpain.2009.09.003 The aim (...) of this randomized double-blind, placebo-controlled, parallel-group study was to evaluate the efficacy, safety, and tolerability of pregabalin in combination with oxycodone or placebo, in patients with either postherpetic neuralgia (PHN) or painful diabetic neuropathy (PDN). After a 7-day washout period, 62 patients were randomized to receive either oxycodone mixture 10 mg/day or placebo mixture for 1 week. Patients were then started on open-label pregabalin (75, 150, 300 and 600 mg/day) according to a forced

EvidenceUpdates2010